Subscribe to Search results

Haemofact No 6 reported that Lord Glenarthur, Parliamentary Under-Secretary of State for Health, speaking in the House of Lords, had made it clear that all home produced Factor 8 would be heat treated from April 1985.

Published on:

The "Daily Mail" published a front page article with the headline "AIDS Virus kills man in Britain".

Published on:

The "Daily Express" published an article titled "Twin bid to curb killer AIDS peril".

Published on:

"The Times" published an article titled "Treated blood cuts Aids risk to haemophiliacs".

Published on:

Douglas Starr, in his book "An Epic History of Medicine and Commerce" commented: "Once AIDS became an acknowledged reality, the drug firms quickly developed screening tests and virus-killing technologies...If they had heeded the warnings of Factor VIII...they would have abandoned the high-risk collection centres sooner and worked more intensively on virus-killing technology."

Published on:

Professor Titmuss published his book "The Gift Relationship".

Published on:

The use of genetically engineered blood clotting agents was announced in October 1988 at the Royal Free Hospital.

Published on:

At a Haemophilia Society Executive Committee meeting it was reported that "the introduction of heat-treated materials has been 'patchy' and that at least one Supra-Region had not yet introduced heat-treated materials."

Published on:

Dr Denis Donohue of the FDA asked the pharmaceutical companies to stop using blood collected from donors likely to have high levels of antibodies to hepatitis.

Published on:

By this time, self-sufficiency had largely been achieved.

Published on:

Experiments were conducted by Dr Shohachi Wada on behalf of Cutter to see if the hepatitis virus with which Factor 9 was spiked could be inactivated whilst the Fator 9 was kept active.

Published on:

Leveton and others published "HIV and the Blood Supply: An Analysis of Crisis Decisionmaking".

Published on:

Dr Edward Shanbrom, who worked as a vice-president of medical and scientific affairs at Hyland, developed the first commercially marketed freeze-dried Factor 8 concentrate. However his suggestions only attracted minimal support in the 1970s and very early 1980s.

Published on:

In Parliament, Baroness Jean Trumpington made clear that NHS products derived from screened plasma would become available for distribution during August 1986 throughout the UK.

Published on:

A surveillance of previously untreated patients for possible virus transmission by BPL Factor 8 and Factor 9 Concentrates, 8Y and 9A, was carried out in September 1986.

Published on:

BPL's work on heat treatment - regarding Factor 9 - only really started in 1982.

Published on:

The concern that heated Factor 9 concentrates might cause thrombosis was one that had to be resolved before its product could be issued. As a result experiments in dogs were conducted prior to clinical trial in humans.

Published on:

Hyland had a research project aimed at eliminating NANBH in factor concentrates that was being hindered by a lack of manpower and adequate funding.

Published on:

In February 1979 Hyland learnt of Behringwerke beginning clinical trials in 1978 in Germany on "Factor VIII Behringwerke" via a report to their head office, later confirmed by another Hyland employee.

Published on:

Hyland had heard that the clinical trials of the Behringwerke product were almost complete and had promising results.

Published on: